Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lionsgate Studios Corp Common Shares (LION) vs Stryker Corporation (SYK) Price & Performance

Lionsgate Studios Corp Common SharesTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Lionsgate Studios Corp Common Shares vs Stryker Corporation — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B), while Stryker Corporation trades at $285 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 32.7× Lionsgate Studios Corp Common Shares's market cap, and Stryker Corporation pays a 1.25% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Stryker Corporation for 22 Days on average.

LIONSYK
Market Cap
$3.31B$108.38B
Volume
2,146,1342,068,363
Sector
TechnologyHealth
52-Week High
$16.40$388.35
52-Week Low
$5.91$269.75
Typical Hold Time
0 Days22 Days
Enterprise Value
$6.82B$119.84B
Dividend Yield
—1.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lionsgate Studios Corp Common Shares

LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.

The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.

Stryker Corporation

Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.

The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LION
100% Buy0% Sell
Avg holding period · 0 Days
SYK
100% Buy0% Sell
Avg holding period · 22 Days

Top news

Latest headlines on both assets

About Lionsgate Studios Corp Common Shares

Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.

Read more on LION →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →